The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Profit Quintuples on Gains from Ranbaxy-Sun Merger
May 15, 2015
- Eisai Earnings Pummeled by Generic Erosions in Japan, US
May 15, 2015
- Mitsubishi Chemical Group to Strengthen Presence in Field of Regenerative Medicine by Acquiring Clio Inc.
May 15, 2015
- Vital KSK Holdings Names Taisuke Murai as President
May 15, 2015
- Kyorin Holdings Names Minoru Hogawa as Next President
May 15, 2015
- Wider Indications Will Give Edge to Plavix AGs: Nichi-Iko Pres.
May 14, 2015
- Takeda Halts PIII Study of Aurora A Kinase Inhibitor for Peripheral T-cell Lymphoma
May 14, 2015
- Blopress AG Gives Lift to ASKA Sales and Profits
May 13, 2015
- Ono’s Operating Profit Declines 40%; NHI Price Reductions, Generics Had Major Negative Impact
May 13, 2015
- Ono to Expand Cancer-Specialized Rep Force to 150 by October Aiming for Additional Indications for Opdivo
May 13, 2015
- Denka Seiken to Start Development of Mass Production Technology for Therapeutic Oncolytic Virus for Cancer Therapy
May 13, 2015
- Ethical Drug Sales Down 5.2% in March: Crecon Report
May 13, 2015
- Shionogi Logs Record Ordinary Profit on Weaker Yen, ViiV Dividends
May 12, 2015
- Sumitomo Dainippon’s Profits Slide as Japan Sales Flounder
May 12, 2015
- Astellas Withdraws NDA for Nateglinide in Combination with DPP-4 Inhibitors
May 12, 2015
- Astellas Earnings Buoyant on Xtandi, Overseas Sales Offset Japan Fall
May 12, 2015
- MTPC Sees Sales Rise for Remicade in FY2015, Mulls M&A under 5-Year Biz Plan
May 11, 2015
- MTPC Sales Up Slightly as Gilenya, Invokana Royalties Eclipse Japan Dip
May 11, 2015
- Takeda, NCC Join Hands on Cancer Drug Research
May 11, 2015
- Takeda to Return Latuda Rights in Europe to Sumitomo Dainippon
May 8, 2015
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…